<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889314</url>
  </required_header>
  <id_info>
    <org_study_id>DESIFOR</org_study_id>
    <nct_id>NCT03889314</nct_id>
  </id_info>
  <brief_title>The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial</brief_title>
  <acronym>DESIFOR</acronym>
  <official_title>The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Heart Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Heart Institute Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll patients who previously were not able to tolerate being on a statin&#xD;
      medication due to muscle-related side effects. Research has shown that many people who have&#xD;
      muscle symptoms on statin therapy do not experience the same side effects if they try it&#xD;
      again later. This study is part of a larger effort to:&#xD;
&#xD;
        -  See how common it is for patients to still be intolerant of statin medication after&#xD;
           trying it a second time; and&#xD;
&#xD;
        -  For those patients who do tolerate being on a statin after trying it a second time, see&#xD;
           how common it is for them to still be taking the statin 3 months after completing the&#xD;
           main part of the study.&#xD;
&#xD;
      Patients who agree to participate will be given a 5 month randomly allocated supply of statin&#xD;
      and placebo and track their symptoms weekly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, double-blinded randomized controlled trial for patients&#xD;
      eligible for statin therapy by current guidelines, but not on statin therapy due to a history&#xD;
      of statin intolerance. Patients will be provided a &quot;DESIFOR&quot; kit which includes 5 randomly&#xD;
      allocated 4-week blister packs of capsules containing either 20mg of rosuvastatin or placebo.&#xD;
      While blinded to treatment, patients will document the severity of musculoskeletal symptoms&#xD;
      every week using a numerical scale. The primary endpoint will be the difference between the&#xD;
      mean musculoskeletal symptom score while randomized to statin therapy compared to the mean&#xD;
      score while on placebo. After completion of the study, the results will be unblinded and&#xD;
      reviewed at a 6 month follow-up visit with the patient and, for patients with symptoms found&#xD;
      to not correlate with statin therapy, a trial of non-blinded statin therapy over the next 3&#xD;
      months will be recommended. This study will serve as a pilot study to determine the&#xD;
      feasibility and potential benefits of a larger multicenter trial with similar aims.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will serve as their own controls in this study whereby they will receive randomly allocated 28-day packets of statin and placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Musculoskeletal intolerance (as documented in study assessments)</measure>
    <time_frame>6 months</time_frame>
    <description>Prevalence of musculoskeletal intolerance between the groups, defined by a lack of statistical difference in the mean musculoskeletal symptom score while on statin therapy compared to placebo, in patients previously identified as statin intolerant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Statin Utilization</measure>
    <time_frame>3 months</time_frame>
    <description>Number of individuals taking statins 3 months post study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Adverse Effect</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>7 day wash-out period between months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <description>Statin Therapy</description>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults age 21-75 years old&#xD;
&#xD;
          -  Statin eligible according to the 2013 ACC/AHA cholesterol guidelines, including&#xD;
             individuals with:&#xD;
&#xD;
               -  Known ASCVD&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  LDL-C &gt; 190mg/dl&#xD;
&#xD;
               -  10-year ASCVD risk &gt;7.5%&#xD;
&#xD;
          -  Statin intolerant&#xD;
&#xD;
               -  Defined by discontinuation of at least 2 separate statins due to potential&#xD;
                  musculoskeletal side effects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, nursing or attempting to become pregnant.&#xD;
&#xD;
          -  Individuals deemed to be at very high CVD risk and therefore appropriate for a PCSK9&#xD;
             inhibitor including:&#xD;
&#xD;
               -  Individuals with familial hypercholesterolemia with markedly elevated LDL-C&#xD;
                  levels&#xD;
&#xD;
               -  Individuals with known ASCVD and recurrent events&#xD;
&#xD;
               -  Individuals who are not otherwise clinically indicated to take 20mg rosuvastatin&#xD;
&#xD;
          -  Individuals who experienced severe reactions in the past, including:&#xD;
&#xD;
               -  Rhabdomyolysis&#xD;
&#xD;
               -  Severe myositis&#xD;
&#xD;
               -  Anaphylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Miedema, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Heart Institute Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gretchen Benson</last_name>
    <phone>612-863-4222</phone>
    <email>gbenson@mhif.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Benson</last_name>
    </contact>
    <investigator>
      <last_name>Michael Miedema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Statin Therapy</keyword>
  <keyword>Prevention</keyword>
  <keyword>High ASCVD Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

